Open AccessRimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
Author(s) -
Richard B. Lipton,
Robert Croop,
Elyse Stock,
David Stock,
Beth Morris,
Marianne Frost,
Gene M. Dubowchik,
Charles M. Conway,
Vladimir Coric,
Peter J. Goadsby
Publication year - 2019
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1811090
Subject(s) - medicine , migraine , placebo , calcitonin gene related peptide , calcitonin , antagonist , gastroenterology , anesthesia , receptor , pathology , neuropeptide , alternative medicine
Calcitonin gene-related peptide receptor has been implicated in the pathogenesis of migraine. Rimegepant is an orally administered, small-molecule, calcitonin gene-related peptide receptor antagonist that may be effective in acute migraine treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom